MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Open accessThe DOI matches its Crossref record; 232 of the 253 references it cites were found in a registry or an index; 117 of the 241 sources its claims cite were checked for support.
Abstract
Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous cellular signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Once activated through phosphorylation, these MAPKs in turn phosphorylate and activate transcription factors present either in the cytoplasm or in the nucleus, leading to the expression of target genes and, as a consequence, they elicit various biological responses. The aim of this work is to provide a comprehensive review focusing on the roles of MAPK signaling pathways in ocular pathophysiology and the potential to influence these for the treatment of eye diseases. We summarize the current knowledge of identified MAPK-targeting compounds in the context of ocular diseases such as macular degeneration, cataract, glaucoma and keratopathy, but also in rare ocular diseases where the cell differentiation, proliferation or migration are defective. Potential therapeutic interventions are also discussed. Additionally, we discuss challenges in overcoming the reported eye toxicity of some MAPK inhibitors.
Overview
CoChat Summary
TL;DR
This review summarizes MAPK signaling in ocular development and disease, covering AMD, diabetic retinopathy, retinal dystrophies, glaucoma, corneal wound healing, dry eye, keratoconus, aniridia, uveitis, and cataract. It highlights potential MAPK-targeting drugs but cautions that systemic MEK/B-Raf inhibition can cause ocular adverse effects such as MEKAR and uveitis.
Key findings
- MAPK subfamilies ERK1/2, JNK1/2/3, p38, and ERK5 are implicated across ocular pathophysiology; ERK generally promotes proliferation/differentiation, while p38/JNK mediate stress, inflammation, apoptosis, and wound healing.
- In AMD, DR, RD, glaucoma, and corneal/aniridia models, specific MAPK inhibition or modulation showed positive effects in vitro and in animals; e.g., MEK inhibitor PD0325901 partially rescued aniridia phenotype in an AAK mouse model, and Duloxetine/Ritanserin restored PAX6 via MEK/ERK inhibition.
- MEK inhibitor–associated retinopathy (MEKAR) features serous detachments of neurosensory retina, commonly bilateral (92%) and multifocal (77%, median 6 foci), with fluid between RPE and interdigitation zone; usually mild/self-limited, but binimetinib effects can fluctuate daily and sometimes lead to subclinical retinal thinning.
- Systemic MAPK inhibitor adverse effects include uveitis with B-Raf inhibitors and central serous chorioretinopathy/MEKAR with MEK inhibitors; Duloxetine eye toxicity included blurred vision (6.7%), uncommon diplopia/dry eye/mydriasis/visual impairment (<1%), and rare glaucoma (<0.1%).
Methods
- Narrative review of published literature on MAPK pathways in ocular pathophysiology and MAPK-targeting compounds; no primary experimental data.
- Evidence synthesized includes in vitro cell studies, animal models, human clinical reports, and bioinformatic/GWAS analyses across retinal, corneal, uveal, and lens diseases.
- Main analysis is qualitative synthesis, with tables summarizing MAPK components and reported adverse effects of specific MAPK inhibitors; no systematic search strategy or meta-analysis is described.
Limitations
- Stated: many conclusions rely on in vitro and animal studies; for cataract, the paper notes insufficient mechanistic in vivo data, and for keratoconus it calls for more targeted research.
- Stated: long-term effects of MAPK inhibitors in populations with specific eye disease are unknown, and adverse effects have been observed mainly with systemic administration and sustained therapeutic schemes; topical or time-limited delivery remains to be investigated.
- Evident from the text: this is a narrative review without a described systematic search or quantitative synthesis, so selection and interpretation biases cannot be excluded.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
108 Valid · 5 Not valid · 97 Not checked · 15 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In retinal ganglion cells, all three branches of the MAPK cascade have been reported to be protective against hydrogen peroxide-induced apoptosis [ 59 ].”
What the sources say
- Disputedcites [59] Ye, 2021, Resveratrol acts via the mitogen-activated protein kinase (MAPK) pathway to protect retinal ganglion cells from apoptosis induced by hydrogen peroxide, Bioengineered sourceExperimental — accuracy not yet measured
The Results section reports the opposite: inhibiting each of the p38, ERK, and JNK branches reduced hydrogen peroxide-induced apoptosis in RGC-5 cells, while activating them worsened it. The Discussion likewise says that resveratrol protects these cells by inhibiting all three branches. No page numbers are provided in our copy. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“haploinsufficiency of JNK2, or both JNK2 and JNK3, results in an increase in ocular hypertension-induced neurodegeneration”
What the sources say
- Disputedcites [130] Harder, 2018, Jnk2 deficiency increases the rate of glaucomatous neurodegeneration in ocular hypertensive DBA/2J mice, Cell Death Dis. sourceExperimental — accuracy not yet measured
The Discussion reports increased neurodegeneration in mice completely deficient in Jnk2, with a small additional effect when Jnk3 was also absent. It says no heterozygous effects were reported, and the Results report no effect of a single null Jnk2 allele in the genotype tested. The claim substitutes haploinsufficiency for the complete deficiency that produced the reported increase. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“while overexpression of p38 and JNK also leads to VEGF expression elevation [ 51 ].”
What the sources say
- Supportedcites [51] Berra, 2000, Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability, J. Biol. Chem. source
The Results report increased VEGF mRNA levels in cells overexpressing p38/HOG or JNK, both at baseline and after anisomycin stimulation. The Discussion likewise states that VEGF mRNA amounts are higher in those cells. The measured elevation is in mRNA expression; the claim does not specify protein levels. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and increased VEGF-A levels are causally implicated in the progressive dysfunction of the RPE [ 46 ].”
What the sources say
- Supportedcites [46] Ablonczy, 2014, Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels, FASEB J. source
The paper reports progressive RPE barrier breakdown in mice with increased VEGF-A and says the increase is sufficient to cause that breakdown (passage 7). It also concludes that increased VEGF-A results in age-dependent RPE dysfunction (passage 4). The evidence is from the mouse model, not a demonstration of causation in humans. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Regarding the JNK activation pathway, the upstream kinases MKK4 and MKK7 have redundant and unique roles in molecular signaling that are important for retinal development, RGC maturation and the response to axonal injury signaling [ 24 ].”
What the sources say
- Partly supportedcites [24] Rausch, 2018, Mkk4 and Mkk7 are important for retinal development and axonal injury-induced retinal ganglion cell death, Cell Death Dis. sourceExperimental — accuracy not yet measured
The Introduction and Discussion report overlapping and distinct roles for MKK4 and MKK7 in retinal development and axonal-injury signaling. The Results show postnatal RGC loss in deficient mice, but do not establish a specific role in RGC maturation, so that part of the claim goes beyond the evidence. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
129 more claims · 60 with their cited sources checked
Create a free account to see all 225 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 73
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Du, S., Shao, J., Xie, D., and Zhang, F. (2020). Decorin inhibits glucose-induced lens epithelial cell apoptosis via suppressing p22phox-p38 MAPK signaling pathway. PLoS ONE, 15.”
Cited work 10.1371/journal.pone.0224251 · retracted 2026-09-24 · notice 10.1371/journal.pone.0358904 · this paper published 2023-02-14
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Li Y. Bai Y.-J. Jiang Y.-R. Yu W.-Z. Shi X. Chen L. Feng J. Sun G.-B. Apelin-13 Is an Early Promoter of Cytoskeleton and Tight Junction in Diabetic Macular Edema via PI-3K/Akt and MAPK/Erk Signaling Pathways BioMed Res. Int. 2018 2018 3242574 10.1155/2018/3242574 29850504 PMC5904819”
Cited work 10.1155/2018/3242574 · retracted 2026-03-31 · notice 10.1155/bmri/9757309 · this paper published 2023-02-14
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“At the same time, a balanced p38/TXNIP/NFκB pathway inhibition is required for proper tight junctions in the inner blood–retinal barrier [87] and for the prevention of macular edema [88–91], while ERK and JNK phosphorylation is inversely correlated with the expression of tight junction components in human retinal endo…”
Cited work 10.1080/21655979.2022.2086351 · retracted 2026-11-20 · notice 10.1080/21655979.2026.2748576 · this paper published 2023-02-14
Citations
Cites
3 retracted
Li, Y., Bai, Y.-J., Jiang, Y.-R., Yu, W.-Z., Shi, X., Chen, L., Feng, J., & Sun, G.-B. (2018) · BioMed Research International · doi:10.1155/2018/3242574 · Cited by 34
RetractedDu, S., Shao, J., Xie, D., & Zhang, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0224251 · Cited by 23
RetractedLiu, T., Zhao, J., & Lin, C. (2022) · Bioengineered · doi:10.1080/21655979.2022.2086351 · Cited by 12 · cited 1×
“At the same time, a balanced p38/TXNIP/NFκB pathway inhibition is required for proper tight junctions in the inner blood–retinal barrier [87] and for the prevention of macular edema [88–91], while ERK and JNK phosphorylation is inversely correlated with the expression of tight junction components in human retinal endo…”
BackgroundRetractedDe Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274 · cited 4×
“ERK1/2 is also activated by growth factors, mitogens, cytokines, osmotic stress, and in response to insulin [2].”
BackgroundInfluentialA Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944 · cited 1×
“More details on the signaling pathway members are given elsewhere [3].”
BackgroundDICER1 deficit induces Alu RNA toxicity in age-related macular degeneration
Kaneko, H., Dridi, S., Tarallo, V., Gelfand, B. D., Fowler, B. J., Cho, W. G., Kleinman, M. E., Ponicsan, S. L., Hauswirth, W. W., Chiodo, V. A., et al. (2011) · Nature · doi:10.1038/nature09830 · Cited by 601 · cited 1×
“A hint for a potential mechanistic involvement of MAPKs in AMD comes from the finding that the RPE of patients with geographic atrophy, an untreatable advanced form of dry (non-neovascular) AMD, have reduced miRNA processing enzyme DICER1, and the ablation of this specific gene is sufficient to induce RPE degeneration…”
BackgroundLuo, L., Li, D.-Q., Doshi, A., Farley, W., Corrales, R. M., & Pflugfelder, S. C. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1145 · Cited by 595 · cited 2×
“, JNK, ERK and p38) were found in a dry eye mouse model [158].”
BackgroundStanciu, M., Wang, Y., Kentor, R., Burke, N., Watkins, S., Kress, G., Reynolds, I., Klann, E., Angiolieri, M. R., Johnson, J. W., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.16.12200 · Cited by 539 · cited 1×
“As it has also been shown that JNK and p38 activation is important for hydrogen peroxide-induced apoptosis in RPE cells [60], it seems that this dual role is dependent on the signal duration, with short-term ERK1/2 signaling being pro-proliferative and, inversely, a persistent ERK1/2 activation leading to cell death […”
BackgroundTargeting dual-specificity phosphatases: Manipulating MAP kinase signalling and immune responses
Jeffrey, K. L., Camps, M., Rommel, C., & Mackay, C. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2289 · Cited by 533 · cited 2×
“cellular processes, such as cell differentiation, proliferation, apoptosis, inflammation, stress responses, and immune defense [4].”
Background
Research works printed but not linked: 1
- Ryan, S.J., Sadda, S.R., Hinton, D.R., Schachat, A.P., Sadda, S.R., Wilkinson, C.P., Wiedemann, P., and Schachat, A.P. (2013). Retina, W.B. Saunders. [5th ed.].
Cited by
Regulation of bone homeostasis: signaling pathways and therapeutic targets
Wu, Z., Li, W., Jiang, K., Lin, Z., Qian, C., Wu, M., Xia, Y., Li, N., Zhang, H., Xiao, H.-X., et al. (2024) · MedComm · doi:10.1002/mco2.657 · Cited by 151
“MAPK, a member of the Ser/Thr kinase family, 189 plays a crucial role in regulating cell proliferation, differentiation, and migration.”
BackgroundTargeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023) · MedComm · doi:10.1002/mco2.308 · Cited by 82
Ocular surface toxicities associated with modern anticancer therapies
Boucher, R. C., Haigh, O. L., Barreau, E., Champiat, S., Lambotte, O., Adam, C., Labétoulle, M., & Rousseau, A. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.10.002 · Cited by 27
Wang, X., Sun, L. D., Han, X., Li, Z., Xing, Y., Chen, X., Xi, R., Sun, Y., Wang, G., & Zhao, P. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5504 · Cited by 33
“Activation of ERK promotes cell survival, whereas the activation of p38 MAPK and JNK plays a critical role in mediating apoptosis in RGCs (41,42). p38 MAPK signaling pathway.”
Progress on the mechanism of natural products alleviating androgenetic alopecia
Wu, S., Kou, X., Niu, Y., Liu, Y., Zheng, B., Ma, J., Liu, M., & Xue, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116022 · Cited by 27
Metadata
- Authors
- Moustardas, P., Aberdam, D., & Lagali, N.
- Affiliations
- Linköping University (SE)
- Inserm (FR)
- Corresponding author
- Moustardas, Petros
- Aberdam, Daniel
- Lagali, Neil
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-02-14
- Volume
- 12
- Issue
- 4
- Pages
- 617
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9954064
- OpenAlex
- W4320919783
- Cited by
- 63
- References
- 253
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 10 · 2023: 7
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DiVA (Linkoping University) (submittedVersion, other-oa)
- HAL (Le Centre pour la Communication Scientifique Directe) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- EJP-RD (EJPRD20-135, 2020-00798, CA-18116)
- AAK-INSIGHT (EJPRD20-135, 2020-00798, CA-18116)
- Swedish Research Council (EJPRD20-135, 2020-00798, CA-18116)
- European Union Cooperation on Science and Technology COST Action (EJPRD20-135, 2020-00798, CA-18116)
- ANIRIDIA-NET (EJPRD20-135, 2020-00798, CA-18116)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- MAPK signaling, eye diseases, macular degeneration, cataract, glaucoma, corneal disease, MAPK inhibitors, ocular toxicity
- MeSH terms
- Phosphorylation, Signal Transduction, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges. https://app.cochat.ai/papers/10.3390/cells12040617
- The paper
- Moustardas, P., Aberdam, D., & Lagali, N. (2023). MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges. Cells. https://doi.org/10.3390/cells12040617
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.